AAHA issues 2026 feline diabetes guidelines with new first-line shift: full analysis

The American Animal Hospital Association has published its 2026 Diabetes Management Guidelines for Cats, marking a significant update in feline primary care and a clear break from the old one-size-fits-both-species approach. Released April 27, 2026, the document separates feline and canine guidance for the first time and highlights how newer therapies, especially SGLT2 inhibitors, are changing frontline treatment decisions in cats. (aaha.org)

That split reflects a broader shift in how feline diabetes is understood. AAHA says the new guideline retains relevant material from its 2018 diabetes guidance, while incorporating newer evidence on diagnosis, treatment, monitoring, risk recognition, and the distinction between cats with true diabetes and cats with hyperglycemia that may not require diabetic treatment. The task force also underscores that some cats can achieve diabetic remission, a dynamic that further supports species-specific recommendations rather than simply adapting canine protocols. (aaha.org)

The most consequential update is the growing preference for SGLT2 inhibitors in appropriate feline patients. According to AAHA, two SGLT2 inhibitors are now licensed in the United States for use in newly diagnosed, otherwise healthy diabetic cats that have not previously been treated with insulin, making them an appropriate option for a substantial proportion of patients. The guideline notes that these drugs act independently of insulin, but also stresses that endogenous insulin is still needed to prevent ketosis, which is why patient selection and early monitoring are so important. (aaha.org)

That recommendation builds on recent regulatory change. FDA approved Elanco’s Bexacat, a bexagliflozin tablet, in December 2022 as the first oral treatment for cats with diabetes mellitus and the first animal-approved SGLT2 inhibitor in any species. FDA later approved Boehringer Ingelheim’s Senvelgo, a velagliflozin oral solution, in August 2023. But the category has also come with scrutiny: FDA issued a 2024 warning letter to Boehringer over promotional claims tied to Senvelgo, citing concerns that materials could understate the boxed warning and monitoring limits tied to diabetic ketoacidosis and euglycemic ketoacidosis risk. (fda.gov)

Beyond drug choice, AAHA’s new feline guideline updates monitoring in ways many practices will notice immediately. It says in-hospital blood glucose curves are no longer recommended for routine diabetic monitoring in cats, reflecting both stress hyperglycemia concerns and the wider availability of CGMs. At the same time, the guideline cautions against overusing CGMs simply to generate numbers in otherwise well-controlled patients, emphasizing that clinicians should monitor the cat, not just the glucose data stream. AAHA Chief Medical Officer Jessica Vogelsang said the split into canine and feline documents recognizes the unique nature of the disease in each species, while co-chair Renee Rucinsky said the updated SGLT2 information and streamlined feline-specific format should make the guidance more useful in practice. (aaha.org)

Why it matters: For veterinary professionals, the guideline gives cover and structure to a practice change that has been unfolding quickly since oral feline diabetes drugs reached the market. It offers algorithms for when SGLT2 therapy fits, when insulin remains the better choice, how to think about diet during initiation, how to use CGMs appropriately, and when to evaluate for remission. That matters operationally as much as medically: case triage, technician workflows, follow-up schedules, and pet parent counseling may all need to change. It also raises the bar for screening, because using these drugs safely depends on identifying cats that are newly diagnosed, otherwise healthy, and not already insulin-treated. (aaha.org)

The commercial backdrop is worth noting, too. AAHA says the guideline was supported by Adapet Medical, Boehringer Ingelheim, Dechra, and Merck Animal Health. That does not negate the clinical value of the document, but it does mean practices may read the recommendations alongside a market that is actively evolving, with manufacturers, regulators, and clinicians still defining how these products should be positioned and monitored in real-world care. (aaha.org)

What to watch: The next phase will be implementation. Watch for clinics to update diabetes intake and screening protocols, standardize how they discuss oral therapy versus insulin with pet parents, and refine monitoring pathways around CGMs, ketone vigilance, and remission assessment after at least 90 days in appropriate cases. (aaha.org)